Leon Bullough
Family · Berkley, MINPI 1396285862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 780 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Gilead at 28.8% of the total. Reporting peaked in 2021 at $4,008 and has fallen 64.9% since, to $1,408 in 2025. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 780 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Viiv Healthcare Company$3K
- Johnson & Johnson$1K
- AbbVie$815
- Novo Nordisk$609
- Merck$502
- plus $3K from 35 others
What the payments were for
- Speaking & faculty fees$781%
- Food & beverage$13,53299%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,731 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 38 | $146,874 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $89,399 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,898 |
| JatenzoTestosterone Undecanoate | 12 | $6,148 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,694 |
| Estradiol | 40 | $1,545 |
| Testosterone Cypionate | 24 | $1,327 |
| Estradiol Valerate | 11 | $1,061 |
| Atorvastatin Calcium | 75 | $890 |
| Duloxetine Hcl | 14 | $628 |
| Levothyroxine Sodium | 28 | $620 |
| Omeprazole | 33 | $598 |
| Tamsulosin Hcl | 14 | $382 |
| Buspirone Hcl | 14 | $329 |
| Carvedilol | 17 | $328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $3,952 | $174,77251 claims |
| Janssen Products, LPSymtuza | $216 | $89,39912 claims |
| Clarus Therapeutics Inc.Jatenzo | $97 | $6,14812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Berkley
- Marna TaylorBerkley$25K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.